Dr. Hiroto Inaba, MD, PhD
Claim this profileSt. Jude Children's Research Hospital
Studies Myeloid Leukemia
Studies Leukemia
3 reported clinical trials
25 drugs studied
Area of expertise
1Myeloid Leukemia
KMT2A positive
NUP98 positive
NPM1 positive
2Leukemia
KMT2A positive
NUP98 positive
NPM1 positive
Affiliated Hospitals
Clinical Trials Hiroto Inaba, MD, PhD is currently running
Venetoclax + Chemotherapy
for Acute Myeloid Leukemia
This is a phase 2 study to test the hypothesis that venetoclax in combination with standard chemotherapy will be tolerable and active in pediatric patients with newly diagnosed acute myeloid leukemia (AML). Primary Objectives: * Establish the tolerability adding venetoclax to standard chemotherapy in pediatric patients with AML * Estimate the proportion of patients who become minimal residual disease (MRD) negative by flow cytometry after one course of venetoclax-based induction therapy Secondary Objectives: - Estimate the rates of complete remission (CR), event-free survival (EFS), and overall survival (OS) in pediatric patients who receive venetoclax-based chemotherapy
Recruiting1 award Phase 2
Revumenib + Chemotherapy
for Acute Myeloid Leukemia
This is a research study to find out if adding a new study drug called revumenib to commonly used chemotherapy drugs is safe and if they have beneficial effects in treating patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that did not go into remission after treatment (refractory) or has come back after treatment (relapsed), and to determine the total dose of the 3-drug combination of revumenib, azacitidine and venetoclax that can be given safely in participants also taking an anti-fungal drug. Primary Objective * To determine the safety and tolerability of revumenib + azacitidine + venetoclax in pediatric patients with relapsed or refractory AML or ALAL. Secondary Objectives * Describe the rates of complete remission (CR), complete remission with incomplete count recovery (CRi), and overall survival for patients treated with revumenib + azacitidine + venetoclax at the recommended phase 2 dose (RP2D).
Recruiting1 award Phase 110 criteria
More about Hiroto Inaba, MD, PhD
Clinical Trial Related7 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Hiroto Inaba, MD, PhD has experience with
- Cytarabine
- Venetoclax
- Idarubicin
- Daunorubicin
- Doxorubicin
- Cyclophosphamide
Breakdown of trials Hiroto Inaba, MD, PhD has run
Myeloid Leukemia
Leukemia
Acute Myeloid Leukemia
Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Hiroto Inaba, MD, PhD specialize in?
Hiroto Inaba, MD, PhD focuses on Myeloid Leukemia and Leukemia. In particular, much of their work with Myeloid Leukemia has involved KMT2A positive patients, or patients who are NUP98 positive.
Is Hiroto Inaba, MD, PhD currently recruiting for clinical trials?
Yes, Hiroto Inaba, MD, PhD is currently recruiting for 2 clinical trials in Memphis Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Hiroto Inaba, MD, PhD has studied deeply?
Yes, Hiroto Inaba, MD, PhD has studied treatments such as Cytarabine, Venetoclax, Idarubicin.
What is the best way to schedule an appointment with Hiroto Inaba, MD, PhD?
Apply for one of the trials that Hiroto Inaba, MD, PhD is conducting.
What is the office address of Hiroto Inaba, MD, PhD?
The office of Hiroto Inaba, MD, PhD is located at: St. Jude Children's Research Hospital, Memphis, Tennessee 38105 United States. This is the address for their practice at the St. Jude Children's Research Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.